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Abstract
Immunoliposomes (IL) containing anti-angiogenic drugs directed selectively to the easily accessible kinase insert domain
containing receptor (KDR) vascular endothelial growth factor (VEGF), which is predominantly expressed on tumour vessels
are a promising tool to inhibit tumour angiogenesis. To explore this strategy, we have prepared fluorescent-labelled IL
presenting antibodies against the KDR receptor (3G2) on their surface. 3G2-IL were composed of egg phosphatidylcholine
and cholesterol (6:4), containing 2 mol% of the new thiol reactive linker lipid O-(3-cholesteryloxycarbonyl)propionyl-OP-m-
maleimido-benzoyl tetraethylene glycol. Specific binding of 3G2-IL to immobilised recombinant KDR was used to show the
maintenance of sufficient immunoreactivity of 3G2 antibodies upon the coupling procedure. 3G2-IL bound to Chinese
hamster ovarian (CHO) cells stably transfected to overexpress KDR to a five times higher amount as compared to mock-
transfected CHO cells. Subsequently, specific binding of 3G2-IL to KDR could also be demonstrated on KDR expressing
cells, human umbilical vein endothelial cells and human microvascular endothelial cells, whereas only low binding of 3G2-IL
to NIH-3T3 mouse fibroblast cells, which do not express KDR, was found. The binding of 3G2-IL to KDR receptors could
not be blocked by VEGF, suggesting that the binding site for VEGF is not identical with the epitope recognised by 3G2. We
could demonstrate that 3G2-IL is able to bind in vitro even in the presence of high levels of VEGF. ß 2000 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Treatment of cancer with chemotherapeutic agents
is causing a wide range of undesired e¡ects limiting
their use and dosage. Liposomes are widely investi-
gated for their properties as site-speci¢c drug carriers
allowing higher drug doses due to fewer systemic side
e¡ects [1,2]. Though conventional liposomes allow
passive tumour site targeting to some degree, the
idea of conjugation of cell-speci¢c antibodies to lipo-
somes (IL, immunoliposomes) has been studied for
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Abbreviations: BSA, bovine serum albumin; DTNB, 5,5P-di-
thiobis-(2-nitrobenzoic acid); FCS, foetal calf serum; EDTA, eth-
ylenediaminetetraacetic acid; HEPES, 4-(2-hydroxyethyl)-pipera-
zine-NP-2-ethanesulfonic acid; HMEC-1, human microvascular
endothelial cells 1; HUVEC, human umbilical vein endothelial
cells ; KDR, kinase insert domain containing receptor; MCS-4,
O-(3-cholesteryloxycarbonyl)propionyl-OP-m-maleimido-benzoyl
tetraethylene glycol ; PBS, phosphate-bu¡ered saline; PCS, pho-
ton correlation spectroscopy; PEG, polyethyleneglycol ; RT,
room temperature; VEGF, vascular endothelial growth factor
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selective drug delivery [3^5]. While the use of these
IL to target tumour cells appears to be promising in
vitro, their use in vivo is very limited due to insu⁄-
cient extravasation and tumour tissue penetration
and consequently IL do not reach their target [6^8].
Tumour-related target sites easily accessible from the
blood stream appeared to be attractive alternatives
for targeting IL.
Angiogenesis is recognised as an important factor
determining tumour growth but also playing a key
role in in£ammatory diseases such as rheumatoid
arthritis or diabetic retinopathy as well as in physio-
logical processes such as the female cycle [9]. Target-
ing angiogenesis is under investigation for cancer
therapy [10]. Structures on the surface of endothelial
cells that are upregulated during the process of an-
giogenesis have been investigated as targets for IL.
Spragg et al. used IL binding to the extracellular
domain of E-selectin to achieve endothelial cell selec-
tive binding [11]. Nicolau et al. reported accumula-
tion of IL in atherosclerotic plaques of rabbits tar-
geting vascular cell adhesion molecule (VCAM 1)
[12]. Sikins et al. investigated the integrin KvL3 which
is essential during vessel growth for targeting tumour
endothelium. They report accumulation of IL in tu-
mours targeting KvL3 [13]. These reports show the
feasibility of vessel targeting with IL but all targets
chosen so far are only moderately speci¢c for tumour
angiogenesis since they are also upregulated in in-
£ammatory tissue.
Tumour angiogenesis is mediated by growth fac-
tors such as vascular endothelial growth factor
(VEGF) [14]. Kinase insert domain containing recep-
tor (KDR) is a speci¢c receptor for VEGF [15].
KDR receptors are tyrosine kinase receptors charac-
terised by a splitted tyrosine kinase catalytic domain,
a single short membrane-spanning sequence and an
extracellular domain containing seven immunoglob-
ulin (Ig)-like loops. Upon VEGF binding, auto- or
transphosphorylation occurs [16]. So far, KDR has
been recognised predominantly on endothelial cells.
Endothelial cells lining vessels in tumour vasculature
are known for upregulated expression of this recep-
tor [17]. Encapsulation of anti-angiogenic drugs in IL
which are selectively targeted to the easily accessible
receptor KDR seem to be a promising tool to inhibit
tumour angiogenesis speci¢cally [18].
The aim of this study was to investigate whether
binding of an antibody targeting KDR (3G2) to lipo-
somes containing the £uorescent dye calcein allows
speci¢c targeting of these IL to endothelial cells. Fur-
thermore, we describe the ¢rst study using O-(3-cho-
lesteryloxycarbonyl)propionyl-OP-m-maleimido-ben-
zoyl tetraethylene glycol (MCS-4) [19], a novel
coupling lipid, to achieve covalent coupling of anti-
bodies to the liposomal surface.
2. Materials and methods
2.1. Materials
Triton X-100 and 4-(2-hydroxyethyl)-piperazine-
NP-2-ethanesulfonic acid (HEPES) were purchased
from Merck (Darmstadt, Germany). 2-Iminothio-
lane, DTNB, bovine Ig were from Sigma (Deissen-
hofen, Germany). Sephadex G25 super¢ne, Sephadex
G75 super¢ne, Sepharose CL-4B were from Pharma-
cia (Uppsala, Sweden). BCA protein assay was pur-
chased from Pierce (Rockford, USA). Egg phospha-
tidylcholine (EPC) was from Lipoid (Ludwigshafen,
Germany). Cholesterol, N-ethylmaleimide and cal-
cein were from Fluka (Buchs, Switzerland). Tryp-
sin^ethylenediaminetetraacetic acid (EDTA) was
from Gibco BRL (Paisly, UK).
2.2. Antibody thiolation
3G2 antibodies (from mice) were incubated with a
20-fold molar excess of 2-iminothiolane (2 mg in
0.4 ml phosphate-bu¡ered saline (PBS)) at room
temperature (RT). The reaction was stopped after
1 h by passing the solution over a column
(10 cmU1 cm) packed with swollen Sephadex G25
super¢ne and £ushed with phosphate bu¡er (0.1 M
Na2POH, pH 7.4). The number of thiol groups per
antibody was calculated by determining the protein
content with the BCA protein assay and thiol group
content by using modi¢cations of an assay based on
5,5P-dithiobis-(2-nitrobenzoic acid) (DTNB) [20]. In
brief, following chromatography, 45 Wl of thiolated
antibodies in solution were mixed with 45 Wl DTNB
solution (0.1 mg per ml phosphate bu¡er, pH 8.0).
The concentration of thiol groups was calculated
from determination of the resulting yellow colour
at 405 nm using a standard curve obtained from
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cysteine. A 20-fold excess of 2-iminothiolane resulted
in 2^3 thiol groups per protein molecule.
2.3. Liposome preparation
MCS-4 was synthesised as previously described by
Kley et al. [19]. Cholesterol was further puri¢ed by
recrystallisation from ethanol. The lipid composition
of the liposomes consisted of EPC/cholesterol/MCS-4
at a molar ratio of 58.8:39.2:2. The lipid mixture
was dissolved in chloroform/methanol 2:1 (v/v) and
dried to a thin ¢lm using a rotary evaporator at 40‡C
under reduced pressure. The lipid ¢lm was rehy-
drated with calcein solution (100 mM calcein,
20 mM HEPES, pH 6.0). The resulting dispersion
of large multilamellar vesicles was extruded 15 times
through a 400 nm polycarbonate membrane using
Lipofast Extruder (Avestin, Ottawa, Ont., Canada).
The temperature during extrusion was kept at about
40‡C. This procedure was repeated with a 100 nm
polycarbonate membrane. After extrusion, liposomes
were puri¢ed using size exclusion column chromatog-
raphy. For each puri¢cation, a 40 cm column with
a diameter of 1 cm was packed with swollen Sepha-
dex G75 super¢ne and £ushed with HEPES bu¡er
(20 mM HEPES, 130 mM NaCl, pH 6.0). During
all parts of the described process, liposomes were
protected from light to minimise calcein degrada-
tion.
2.4. Coupling of antibodies to liposomes
Freshly prepared liposomes were incubated with
freshly thiolated antibodies. The pH was adjusted
to 7.6 using 0.01 N NaOH. The coupling reaction
was carried out at 4‡C for 12 h under protection
from light and constant rotation. By adding a 100-
fold molar excess of N-ethylmaleimide (with respect
to the protein content), the reaction was stopped.
After 1 h of blocking excess thiol groups with N-
ethylmaleimide IL were puri¢ed by size extrusion
column chromatography under protection from light.
For this purpose, a 40 cm column with a diameter of
1 cm was packed with Sepharose CL-4B and £ushed
with HEPES bu¡er (20 mM HEPES, 130 mM NaCl,
pH 7.4). The liposome dispersion was kept at 4‡C for
a maximum of 7 days.
2.5. IL characterisation
Total lipid was quanti¢ed according to the method
of Eibl and Lands [21]. Proteins were separated from
lipids according to Wessel and Flu«gge [22]. Protein
content was determined by dot blot with bovine Ig as
standard. The amount of coupled protein to lipo-
somes is expressed as Wg protein to Wmol total lipid.
The liposome size was determined using a Nicomp
370 photon correlation spectroscopy (PCS) system
(Nicomp, USA).
2.6. Binding of IL to recombinant receptors
In this study, we used recombinant KDR receptor
protein consisting of the entire extracellular domain
of human KDR receptors fused on the C-terminal
end with the Fc portion of human IgG1 [23]. This
fusion protein was expressed in baculo-virus-infected
insect cells (Martiny-Baron, unpublished). Prior to
these binding experiments with 3G2-IL, 3G2 had
been demonstrated to bind to this recombinant re-
ceptor with high a⁄nity (Reusch, unpublished obser-
vations). One Wg recombinant Fc fusion proteins dis-
solved in 100 Wl PBS was incubated per well of a 96-
well MaxiSorp plate overnight at 4‡C. Unspeci¢c
binding was blocked adding 100 Wl of PBS contain-
ing 0.1% Tween-20 and 1% bovine serum albumin
(BSA). Each well was subsequently washed three
times with PBS. In each well, an appropriate amount
of liposome dispersion was added according to the
desired ¢nal liposome concentration and diluted up
to 100 Wl per well with 0.5% BSA in PBS. Incubation
was carried out at RT for 2 h under protection from
light. Incubation was followed by washing with PBS.
Bound liposomes were lysed by adding 0.1 ml lysis
bu¡er (5% Triton X-100, 50 mM HEPES, pH 7.5)
and warming up to 60‡C for 30 min followed by
centrifugation (100Ug, 5 min).
2.7. Cell culture
NIH-3T3 cells were maintained in Dulbecco’s
MOD Eagle medium/10% foetal calf serum (FCS)/
1% streptomycin/1% penicillin and Chinese hamster
ovarian cells (CHO cells) were kept in MEM Alpha
Medium/10% FCS/1% streptomycin/1% penicillin/
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2.5% geneticin at 37‡C/10% CO2 in a humi¢ed at-
mosphere. Human umbilical vein endothelial cells
(HUVEC) and human microvascular endothelial
cells 1 (HMEC-1) were maintained in endothelial
cell growth medium/5% FCS at 37‡C/5% CO2 in a
humi¢ed atmosphere.
2.8. Binding of IL to cells
CHO cells have been transfected with pBKCMV
modi¢ed with human KDR sequence and demon-
strated to express KDR stably (F. Totzke, unpub-
lished results). CHO-mock cells have been trans-
fected with unmodi¢ed pBKCMV. Cells cultured as
monolayers were brought into suspension with tryp-
sin^EDTA and washed with medium. Cells (2U106
cells/ml) were kept in suspension with medium and
incubated with liposomes over 3 h at 37‡C under
constant rotation. Unbound liposomes were removed
by washing three times with PBS. Subsequently
bound liposomes and cells were lysed by adding
0.25 ml of lysis bu¡er (5% Triton X-100, 50 mM
HEPES, pH 7.5) and warming up to 60‡C for
30 min followed by centrifugation (100Ug, 5 min).
Incubation in the presence of VEGF 165 was per-
formed as follows: 100 Wg recombinant VEGF [33]
was incubated with CHO-KDR, CHO-mock cells
and HUVEC in the presence of liposomes. The num-
ber of cells was determined using a Coulter Counter
71 (Coulter Eurodiagnostics, Germany). Speci¢city
of 3G2-IL binding to KDR was demonstrated by
competition of binding with free 3G2 antibody:
50 Wg 3G2 was added to cell suspensions 30 min
prior to addition of liposomes and incubated at
37‡C. Subsequently, liposomes were added and incu-
bation performed as described above.
2.9. Measurement of liposome binding
The amount of liposomes bound to cells or re-
combinant receptors was measured by £uorescence
intensity. Using lysis bu¡er (5% Triton X-100,
50 mM HEPES, pH 7.5), encapsulated calcein was
released and due to dilution dequenched. Fluores-
cence intensity was detected using a £uorescence
spectrometer LS 50 B (Perkin-Elmer, Germany) at
excitation wavelength 480 nm and emission wave-
length 520 nm.
3. Results and discussion
3.1. Preparation of calcein containing liposomes
In this study, a new coupling lipid, MCS-4, re-
cently described by Kley et al. [19] was used for
covalent binding of antibodies to the liposomal sur-
face.
Incorporation of MCS-4 into liposome bilayers
was easy and showed no e¡ect on the liposomal
size. 10 Wg thiolated 3G2 was incubated with
10 Wmol lipid, resulting in a coupling e⁄ciency of
38%. The mean size of liposomes resulting was in
the range of 90^200 nm as determined by PCS.
MCS-4 is a member of a new family of coupling
lipids based on a cholesterol anchor, a chain of poly-
ethyleneglycol (PEG) of variable length and male-
imide as reactive group. Thus it is possible to cova-
lently couple thiolated proteins to the distal end of
PEG chains. PEG on the surface of liposomes is
known to enhance circulation time [24^27]. To allow
coupled antibodies to interact with their antigen cou-
pling at the distal end of these chains has been dem-
onstrated to be suitable [28^31]. This is the ¢rst re-
port of successful application of a member of this
class of new coupling lipids.
With a tetraethyleneglycol spacer containing cou-
pling lipid as we used in this study, we do not expect
to enhance circulation time for liposomes in vivo.
MCS-4 serves as a model for applications of this
new kind of coupling lipid. Further studies using
longer spacer chains are under way.
3.2. Binding of IL to immobilised KDR receptors
To demonstrate binding of 3G2-IL to KDR recep-
tors, we initially chose a cell free approach. Re-
combinant KDR receptor fragments were immobi-
lised and subsequently incubated with 3G2-IL and
respective liposomes bearing no antibodies (unconju-
gated liposomes).
As shown in Fig. 1, the binding of 3G2-IL to
immobilised recombinant KDR exceeded the binding
of unconjugated liposomes at both liposome concen-
trations (0.1 mM and 0.5 mM). At both concentra-
tions, binding of unconjugated liposomes was less
than 10% of the binding observed with 3G2-IL. A
5-fold increase of the liposome concentration (0.1^
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0.5 mM) did not lead to similar enhancement of
3G2-IL binding.
The advantage of this cell free approach we are
presenting in this study lies in the chance to study
IL^antigen interactions not in£uenced by cell-depen-
dent factors such as antigen density, surface accessi-
bility or endocytosis. As demonstrated in this experi-
ment, 3G2 antibodies coupled to liposomes are able
to bind to KDR receptors despite manipulation dur-
ing coupling procedures. Apparently, coupling of
3G2 to the liposomal surface seemed to orientate
su⁄cient amount of the antibody in such a manner
that binding to the antigen was possible.
3.3. Binding of 3G2-IL to CHO cells
CHO cells were transfected either with an empty
vector (CHO-mock) or transfected to stably express
KDR (CHO-KDR). Using these cells, we were able
to investigate unspeci¢c interactions of 3G2-IL with
cells by comparing binding of 3G2-IL on CHO-KDR
cells with binding on CHO-mock cells. Unconjugated
liposomes were used in further control experiments
demonstrating liposome^cell interactions independ-
ent of antibody ligand-mediated binding.
CHO-mock/CHO-KDR cells in suspension were
incubated with increasing concentrations of either
3G2-IL or unconjugated liposomes. As shown in
Fig. 2, unconjugated liposomes showed only minimal
binding to both cell types in all three concentrations.
On the other hand, 3G2-IL could bind to the antigen
for 3G2 antibodies, KDR receptors, on CHO-KDR
cells which is re£ected by high £uorescence intensity.
Unlike with unconjugated liposomes, experiments
with 3G2-IL on CHO-mock cells showed increased
£uorescence intensity. The interactions of 3G2-IL
with CHO-mock cells have to be considered as un-
speci¢c and not based on antibody^antigen recogni-
tion. Because unconjugated liposomes did not show
signi¢cant liposome binding, liposomes in themselves
did not carry characteristics responsible for unspe-
ci¢c interactions. Hence, unspeci¢c interactions
were dependent on the presence of antibodies on
the liposomal surface. Na«ssander et al. [7] reported
changes in the zeta potential during the process of
Fab’ coupling to negatively charged liposomes. The
zeta potential was reported to become more positive
(34 mV to 312 mV). We assume that the neutral
liposomes used in this study underwent similar alter-
ations resulting in positively charged liposomes
which can undergo electrostatic interactions with
negatively charged cell membranes.
Unspeci¢c binding doubled when increasing the
liposome concentration from 0.05 mM to 0.1 mM
but increased by seven times this value when the
Fig. 2. Binding of 3G2-IL and unconjugated liposomes to
CHO-mock and CHO-KDR cells. CHO-mock and CHO-KDR
cells were brought into suspension at a concentration of 2U106
cells/ml and incubated with di¡erent concentrations of either
3G2-IL or unconjugated liposomes over 3 h at 37‡C (both lipo-
somes containing equal amount of calcein); following two
washing steps, bound liposomes were lysed and calcein £uores-
cence was determined.
Fig. 1. Binding of 3G2-IL to recombinant KDR receptors. Re-
combinant KDR receptors were immobilised and incubated
with either 3G2-IL or unconjugated liposomes over 3 h at RT
(both liposomes containing equal amount of calcein); bound
liposomes were lysed and calcein £uorescence was determined.
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liposome concentration was further increased to
0.2 mM. Taking the above made conclusions into
consideration, the values obtained for the binding
of 3G2-IL to CHO-KDR cells must be corrected
for this portion which is independent of antigen pres-
ence. These values represent antigen-speci¢c 3G2-IL
binding solely due to binding of 3G2 to KDR recep-
tors. For the concentrations of 0.05 and 0.1 mM, the
antigen-speci¢c binding amounted to more than
three quarters of total binding. For the concentration
of 0.2 mM, the antigen-speci¢c binding decreased to
about half of total binding mainly as a consequence
of growing antigen-independent binding.
3.4. Binding of 3G2-IL to endothelial cells
To investigate 3G2-IL binding to cells naturally
expressing KDR, we performed binding experiments
with HUVEC and HMEC-1 and compared results
for these cells with mouse ¢broblasts (NIH-3T3).
Taking results of binding experiments with CHO-
mock/CHO-KDR cells into account, we chose a lipo-
some concentration of 0.1 mM for 3G2-IL respec-
tively unconjugated liposomes for following experi-
ments. At this concentration, the ratio between
unspeci¢c e¡ects and speci¢c binding of 3G2-IL
was expected to be minimal.
3G2-IL showed high binding values on both endo-
thelial cell lines with only low binding of unconju-
gated liposomes (Fig. 3A). The highest binding of
3G2-IL could be observed on HUVEC. On
HMEC-1 measured £uorescence intensity for incuba-
tion with 3G2-IL was still in the range of 3G2-IL
binding to CHO-KDR cells. We speculate that di¡er-
ences in £uorescence intensity might be due to di¡er-
ences in receptor density or accessibility of the recep-
tor on these cells. NIH-3T3 cells do not express
C
Fig. 3. A: Binding of 3G2-IL and unconjugated liposomes to
endothelial cells compared to the binding to receptor negative
cells. CHO-mock and CHO-KDR cells as well as two endothe-
lial cell lines (HUVEC and HMEC-1) and a ¢broblast cell line
(NIH-3T3) were brought into suspension at a concentration of
2U106 cells/ml and incubated with 0.1 mM of either 3G2-IL or
unconjugated liposomes over 3 h at 37‡C (both liposomes con-
taining equal amount of calcein); following two washing steps,
bound liposomes were lysed and calcein £uorescence was deter-
mined. B: In£uence of 3G2 pre-incubation on binding of 3G2-
IL. CHO-mock and CHO-KDR cells as well as HUVEC cells
were incubated with 50 Wg 3G2 antibodies each prior to incuba-
tion with 3G2-IL; blocking KDR receptors with free 3G2 anti-
bodies speci¢city of 3G2-IL binding to receptor expressing cells
was determined. C: In£uence of VEGF on 3G2-IL binding.
CHO and CHO-KDR cells were incubated with 3G2-IL in the
presence of 100 Wg VEGF in order to determine interactions of
VEGF binding to KDR receptors and 3G2-IL binding to KDR
expressing cells.
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KDR. Consequently, the binding of both types of
liposomes was in the same range as the binding of
these liposomes to CHO-mock cells.
To investigate the amount of unspeci¢c binding of
3G2-IL to endothelial cells, blocking experiments
were performed. Prior to incubation with 3G2-IL
CHO, CHO-KDR and HUVEC were incubated
with soluble 3G2 antibodies to block speci¢c bind-
ing. Subsequently, we added 3G2-IL. Results ob-
tained (Fig. 3B) were compared to incubation of
3G2-IL with respective cells without 3G2 antibody
pre-incubation. As shown in Fig. 3B, no speci¢c
binding of 3G2-IL to any cell type could be observed
after pre-incubation of cells with soluble 3G2 anti-
bodies. Thus HUVEC did not only prove to have a
high total £uorescence intensity but considering only
small values of unspeci¢c binding, as seen with incu-
bation after blocking of KDR receptors, it could be
shown that speci¢c binding is by far the main mech-
anism of 3G2-IL binding. This result is similar to
results found for CHO-mock and CHO-KDR cells
(0.1 mM).
These results taken together not only demonstrate
KDR receptor selective binding of 3G2-IL but also a
possible in£uence of antigen density on IL binding as
previously described for other target ligands. In£u-
ence of KDR receptor density on binding could fa-
vour our model of IL utilisation for endothelial cell
targeting selective for tumour endothelium. We may
expect only neglectable binding of 3G2-IL to endo-
thelium outside tumours with only traces of KDR
receptor expression but accumulation in areas with
high KDR receptor density, i.e. tumour vessels.
3.5. 3G2-IL binding in the presence of VEGF
VEGF is found in high levels in many tumours
and systemic circulation [32]. Thus prior to in vivo
experiments, it appeared to be necessary to investi-
gate the in£uence of the natural ligand VEGF on
3G2-IL binding to KDR receptors. For this experi-
ment, we pre-incubated CHO-mock and CHO-KDR
cells with an excess amount of recombinant VEGF
[33]. Subsequently, these cells were incubated with
3G2-IL.
As shown in Fig. 3C, no signi¢cant change in
binding characteristics could be observed. Taking
these results, we could conclude that 3G2 recognises
structures on KDR which are not responsible for
VEGF binding. Nor is this epitope altered or made
inaccessible for 3G2 following VEGF binding and
phosphorylation of the receptor. Thus, 3G2-IL are
generally able to bind to KDR receptors expressed in
tumour vessels where increased amount of VEGF is
expected, regardless of whether the receptor is acti-
vated or not.
4. Conclusions
In this study, we were using a new coupling lipid
(MCS-4) to covalently bind antibodies to the liposo-
mal surface. Using 3G2 antibodies recognising KDR
receptors coupled to liposomes (3G2-IL), we could
demonstrate binding of these 3G2-IL to immobilised
recombinant KDR receptors. Furthermore, experi-
ments with CHO cells expressing KDR after stable
transfection (CHO-KDR cells) con¢rmed binding of
3G2-IL to KDR receptor expressing cells. Finally,
we could con¢rm these results with human endothe-
lial cells HUVEC and HMEC-1 while the low degree
of binding of 3G2-IL to the ¢broblast cell line NIH-
3T3 and CHO-mock determined speci¢city of 3G2-
IL binding to KDR receptors. Blocking KDR recep-
tors prior to incubation with free 3G2 antibodies
demonstrated speci¢city of 3G2-IL for KDR express-
ing cells. The presence of the natural ligand for KDR
receptors, VEGF, did not interfere with 3G2-IL
binding.
In a further step, in vivo studies will investigate the
ability of 3G2-IL to accumulate in tumour blood
vessels. IL are expected to serve as optimised vehicles
for anti-angiogenic drugs. For optimisation of IL for
use in systemic application, variation of the spacer
length between the cholesterol and reactive group of
the new group of cholesterol-based coupling lipids is
possible.
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